Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

por Groves, M D, Puduvalli, V K, Gilbert, M R, Levin, V A, Conrad, C A, Liu, V H, Hunter, K, Meyers, C, Hess, K R, Alfred Yung, W K
Publicado 2009

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

por Litton, J. K., Scoggins, M., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., Gomez, J. Schwartz, Mittendorf, E. A., Thompson, A., Helgason, T., Mills, G. B., Piwnica-Worms, H., Arun, B. K.
Publicado 2017

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

por Cascone, T., Sacks, R.L., Subbiah, I.M., Drobnitzky, N., Piha-Paul, S.A., Hong, D.S., Hess, K.R., Amini, B., Bhatt, T., Fu, S., Naing, A., Janku, F., Karp, D., Falchook, G.S., Conley, A.P., Sherman, S.I., Meric-Bernstam, F., Ryan, A.J., Heymach, J.V., Subbiah, V.
Publicado 2021